Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

House Democrats Push Their Health Reform Plan
House Democrats" health care bill draft released Friday is likely to survive relatively intact, "including a robust new Medicare-like public health plan that would compete with private companies in a national health insurance exchange," Roll Call reports.
generic viagra online
Brazil Proves Developing Countries Can Use Generic Medicines To Fight HIV/AIDS Epidemic
Brazil"s nearly two-decade effort to treat people living with HIV and AIDS shows that developing countries can successfully combat the epidemic. Inexpensive generic medicines are a large part of the solution, say researchers from Brown University and the Harvard School of Public Health.
News of the day
Jaloma Pacifiers Recalled Due To Choking Hazard
The Connecticut Department of Consumer Protection is notifying consumers about a voluntary recall announced by the U.S. Consumer Product Safety Commission. The recalled Jaloma Pacifiers were sold in retail stores in New Jersey and New York from February 2008 through March 2009, for approximately $1.00. Although not sold in Connecticut stores, this recalled product may have been purchased while visiting the above noted states or may have been sent to Connecticut as a gift. The pacifiers were manufactured in Mexico and imported by Gromex Inc., of Passaic, New Jersey. Although no injuries and/or incidents have been reported, the potential for injury is high due to the pacifier mouth guard and the ventilation holes are too small and fail to meet federal safety standards, for this reason, the pacifier poses a choking hazard to young children.
Sexual Health

Predicting Higher Risk For Prostate Cancer Diagnosis

High-grade prostatic intraepithelial neoplasia (HGPIN) carries a high predictive value for future diagnosis of prostate cancer. Research published in the open access journal BMC Urology has shown that 41.8% of patients whose extended core biopsy led to an initial diagnosis of HGPIN were subsequently diagnosed with prostate cancer. Paras Singh and Francis Martin, from Lancashire Teaching Hospitals NHS Foundation Trust and Lancaster University, along with their co-workers, conducted a retrospective analysis of the institution"s pathology database, investigating the occurrence of prostate cancer in patients initially diagnosed with HGPIN. They also calculated the risk of developing prostate cancer based on initial levels of PSA. They said, "Of 2,192 biopsied patients, there were 88 cases of isolated HGPIN of which 67 patients underwent one or more repeat biopsies. In this repeat-biopsy group, 28 prostate cancer diagnoses were made. Age at first biopsy, higher baseline PSA and higher change in PSA were all predictive of cancer detection on repeat biopsies". There has been speculation that an initial diagnosis of HGPIN may not be a useful indicator of the future risk of prostate cancer. The authors acknowledge that the 41.8% risk they identified is higher than that found by most contemporary studies, but point out that it is comparable to an earlier US-based study from when there was lower level of PSA screening, perhaps similar to the current situation in the UK. The researchers conclude, "HGPIN carries a high predictive value for future diagnosis of prostate cancer. Based on our results, we recommend delaying the first repeat biopsy at low PSA range but to have a shorter interval to repeat biopsies at intermediate and higher PSA ranges". Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience Paras B Singh, Caroline M Nicholson, Narasimhan Ragavan, Rosemary A Blades, Francis L Martin and Shyam S Matanhelia BMC Urology (in press) http://www.biomedcentral.com/bmcurol/ Graeme Baldwin BioMed Central


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009